Suppr超能文献

医疗保险部分 D 人群中全面和非全面药物审查导致的积极药物变化。

Positive Medication Changes Resulting from Comprehensive and Noncomprehensive Medication Reviews in a Medicare Part D Population.

机构信息

1 University of Arizona Medication Management Center, Tucson, Arizona.

2 University of Arizona College of Pharmacy, Tucson, Arizona.

出版信息

J Manag Care Spec Pharm. 2017 Mar;23(3):388-394. doi: 10.18553/jmcp.2017.23.3.388.

Abstract

BACKGROUND

Health care organizations face the challenge of reducing costs while improving health outcomes. Currently, more than 39 million seniors are enrolled in a Medicare Part D prescription benefit plan, many of whom also qualify for medication therapy management (MTM) services. MTM programs provide valuable services designed to prevent or resolve medication-related problems (MRPs). Two core components of all MTM programs include comprehensive medication reviews (CMRs) with followup interventions and focused non-CMR interventions. Currently, there is limited research comparing the rate of MRPs resolved by CMR and non-CMR interventions.

OBJECTIVE

To determine whether CMRs versus non-CMR interventions resulted in more pharmacist-initiated intervention recommendations and positive medication changes.

METHODS

This retrospective, cross-sectional quality improvement project evaluated outcomes for individuals who received interventions following a CMR compared with those who received non-CMR interventions as part of a comprehensive MTM program. For this project, eligible individuals qualified for an MTM program. A positive medication change was defined as the addition of an appropriate medication or the removal of an inappropriate medication within 120 days of a pharmacist recommendation. Differences between the groups were calculated using the Wilcoxon rank sum test.

RESULTS

During the 2-year period (2012 and 2013), 788,756 beneficiaries were enrolled in the MTM program and evaluated for potential MRPs. In both years, pharmacists recommended more medication changes per member for those receiving a CMR (0.81 in 2012 and 0.82 in 2013) compared with the non-CMR group (0.68 in 2012 and 0.61 in 2013; P value < 0.001 for both years). However, recommendations made via non-CMR interventions (representing the vast majority of all medication reviews) were more likely to result in a positive medication change (OR = 1.24, 95% CI = 1.21-1.28 for 2012; OR = 1.26, 95% CI = 1.22-1.30 for 2013).

CONCLUSIONS

These quality improvement project results suggest that Medicare Part D beneficiaries participating in a university-based MTM program who received non-CMR interventions had a higher likelihood of having positive medication changes than those receiving CMRs. These results are enlightening and may provide initial evidence to support inclusion of a non-CMR performance metric for the Centers for Medicare & Medicaid Service's star ratings for MTM programs.

DISCLOSURES

No outside funding supported this study. The University of Arizona Medication Management Center (UAMMC)/SinfoniaRx provides grant funding to the University of Arizona for research. Augustine reports support from the UAMMC and ownership of Pfizer stock and was a graduate student at the University of Arizona College of Pharmacy at the time of this study. The authors report no other potential conflicts of interest. Buhl and Augustine contributed study concept and design, collected the data, and wrote the manuscript. Data interpretation was performed by all the authors. Taylor, Warholak, Augustine, and Martin revised the manuscript.

摘要

背景

医疗保健组织面临着在提高医疗效果的同时降低成本的挑战。目前,有超过 3900 万老年人参加了医疗保险部分 D 处方福利计划,其中许多人也有资格获得药物治疗管理 (MTM) 服务。MTM 计划提供了有价值的服务,旨在预防或解决药物相关问题 (MRPs)。所有 MTM 计划的两个核心组成部分包括全面药物审查 (CMR) 及其后续干预措施和重点非 CMR 干预措施。目前,关于 CMR 和非 CMR 干预措施解决 MRPs 的速度的研究有限。

目的

确定 CMR 与非 CMR 干预措施相比,是否会导致更多的药剂师发起干预建议和积极的药物改变。

方法

这项回顾性、横断面质量改进项目评估了接受 CMR 后接受干预的个体与作为综合 MTM 计划一部分接受非 CMR 干预的个体的结果。对于这个项目,符合条件的个体有资格参加 MTM 计划。一个积极的药物改变被定义为在药剂师建议后的 120 天内添加适当的药物或去除不适当的药物。使用 Wilcoxon 秩和检验计算两组之间的差异。

结果

在 2012 年和 2013 年的两年期间,有 788756 名受益人为参加 MTM 计划并评估潜在的 MRPs。在这两年中,接受 CMR 的患者每个成员的药物变化建议更多(2012 年为 0.81,2013 年为 0.82),而非 CMR 组(2012 年为 0.68,2013 年为 0.61;两个年份的 P 值均<0.001)。然而,通过非 CMR 干预措施(代表所有药物审查的绝大多数)做出的建议更有可能导致积极的药物变化(2012 年的比值比 [OR] = 1.24,95%置信区间 [CI] = 1.21-1.28;2013 年的 OR = 1.26,95% CI = 1.22-1.30)。

结论

这些质量改进项目的结果表明,参加基于大学的 MTM 计划的医疗保险 D 部分受益人为参与非 CMR 干预措施的人比接受 CMR 的人更有可能有积极的药物变化。这些结果具有启发性,可能为支持医疗保险和医疗补助服务中心的 MTM 计划星级评定纳入非 CMR 绩效指标提供初步证据。

披露

没有外部资金支持这项研究。亚利桑那大学药物管理中心 (UAMMC)/SinfoniaRx 为亚利桑那大学的研究提供赠款资金。奥古斯丁报告说他从 UAMMC 获得支持并拥有辉瑞的股票,并且在这项研究进行时他是亚利桑那大学药学院的研究生。作者报告没有其他潜在的利益冲突。Buhl 和奥古斯丁提出了研究概念和设计,收集了数据,并撰写了手稿。所有作者都进行了数据解释。Taylor、Warholak、奥古斯丁和 Martin 对稿件进行了修订。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验